Data at the International Epilepsy Congress in Istanbul show Fycompa (perampanel), from Eisai, may significantly reduce seizure frequency, both in...
Results from the final pivotal Phase III study and long term Phase III extension study of Epilepsy drug Fycompa (perampanel),...
Fycompa (perampanel) is indicated for the adjunctive treatment of - partial-onset seizures (POS) with or without secondarily generalised seizures in patients from 4 years of age and older. - primary generalised tonic-clonic (PGTC) seizures in patients from 7 years of age and older with idiopathic generalised epilepsy (IGE).
Eisai announced that the results of its Phase III trial (Study 332) for Fycompa (perampanel) CIII have been published in...
The FDA has approved Fycompa (perampanel) CIII Oral Suspension, from Eisai, as adjunctive therapy for the treatment of partial-onset seizures...